Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling

Nature Biotechnology

Volumn 23, Issue 10, 2005, Pages 1303-1307

  Evans, Michael J ^a   Saghatelian, Alan ^a   Sorensen, Erik J ^b   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYME INHIBITION; ENZYMES; PERTURBATION TECHNIQUES; REACTION KINETICS; TUMORS;

BIOACTIVE COMPOUNDS; CELL-BASED SCREENS; GLYCOLYSIS; PROTEIN FUNCTION;

GENETIC ENGINEERING;

ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; FR 901464; FUMAGILLIN; GLYCOLYTIC ENZYME; LUMINACIN D; MJE 3; NATURAL PRODUCT; PHOSPHOGLYCERATE MUTASE 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; COVALENT BOND; DRUG DETERMINATION; DRUG INHIBITION; ENZYME INHIBITION; FUNCTIONAL PROTEOMICS; GENOMICS; GLYCOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; TARGET CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHOSPHOGLYCERATE MUTASE; PROTEIN INTERACTION MAPPING; PROTEOME;

EID: 27144510184     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1149     Document Type: Article

References (30)

1. Strausberg, R.L. & Schreiber, S.L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294-295 (2003).
2. Stockwell, B.R. Exploring biology with small organic molecules. Nature 432, 846-854 (2004).
3. Burdine, L. & Kodadek, T. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11, 593-597 (2004).
4. Clemons, P.A. Complex phenotypic assays in high-throughput screening. Curr. Opin. Chem. Biol. 8, 334-338 (2004).
5. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
6. Dolma, S., Lessnick, S.L., Hahn, W.C. & Stockwell, B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
7. Wu, X., Ding, S., Ding, Q., Gray, N.S. & Schultz, P.G. Small molecules that induce cardiomyogenesis in embryonic stem cells. J. Am. Chem. Soc. 126, 1590-1591 (2004).
8. Luesch, H. et al. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem. Biol. 12, 55-63 (2005).
9. Robertson, J.G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 44, 5561-5571 (2005).
10. Drahl, C., Cravatt, B.F. & Sorensen, E.J. Protein-reactive natural products. Angew. Chem. Int. Edn. Engl. 44, 5788-5809 (2005).
11. Liu, S., Widom, J., Kemp, C.W., Crews, C.M. & Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282, 1324-1327 (1998).
12. Wakabayashi, T., Kageyama-Kawase, R., Naruse, N., Funahashi, Y. & Yoshimatsu, K. Luminacins: a family of capillary tube formation inhibitors from Streptomyces sp. II. Biological activities. J. Antibiot. (Tokyo) 53, 591-596 (2000).
13. Nakajima, H. et al. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J. Antibiot. (Tokyo) 49, 1204-1211 (1996).
14. Speers, A.E., Adam, G.C. & Cravatt, B.F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125, 4686-4687 (2003).
15. Speers, A.E. & Cravatt, B.F. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11, 535-546 (2004).
16. Taunton, J. How to starve a tumor. Chem. Biol. 4, 493-496 (1997).
17. Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S. & Greenbaum, D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7, 27-38 (2000).
18. Herrchen, M. & Legler, G. Identification of an essential carboxylate group at the active site of lacZ beta-galactosidase from Escherichia coli. Eur. J. Biochem. 138, 527-531 (1984).
19. White, M.F. & Fothergill-Gilmore, L.A. Development of a mutagenesis, expression and purification system for yeast phosphoglycerate mutase. Investigation of the role of active-site His181. Eur. J. Biochem. 207, 709-714 (1992).
20. Speers, A.E. & Cravatt, B.F. A tandem orthogonal proteolysis strategy for high-content chemical proteomics. J. Am. Chem. Soc. 127, 10018-10019 (2005).
21. Wang, Y. et al. Crystal structure of human B-type phosphoglycerate mutase bound with citrate. Biochem. Biophys. Res. Commun. 331, 1207-1215 (2005).
22. Sirois, S., Hatzakis, G., Wei, D., Du, Q. & Chou, K.C. Assessment of chemical libraries for their druggability. Comput. Biol. Chem. 29, 55-67 (2005).
23. Gatenby, R.A. & Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899 (2004).
24. Rigden, D.J., Walter, R.A., Phillips, S.E. & Fothergill-Gilmore, L.A. Polyanionic inhibitors of phosphoglycerate mutase: combined structural and biochemical analysis. J. Mol. Biol. 289, 691-699 (1999).
25. Engel, M., Mazurek, S., Eigenbrodt, E. & Welter, C. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J. Biol. Chem. 279, 35803-35812 (2004).
26. Kondoh, H. et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65, 177-185 (2005).
27. Kung, C. et al. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl. Acad. Sci. USA 102, 3587-3592 (2005).
28. Wong, S. et al. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliterative disorder cell populations. Proc. Natl. Acad. Sci. USA 101, 17456-17461 (2004).
29. Mazurek, S., Zwerschke, W., Jansen-Durr, P. & Eigenbrodt, E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem. J. 356, 247-256 (2001).
30. Leung, D., Hardouin, C., Boger, D.L. & Cravatt, B.F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21, 687-691 (2003).